Ben Bradley, our Head of Partnerships and Licensing, is attending Gut-Brain Axis 2018, part of the Biotech Pharma Summit conference series in Paris September 6 & 7. This year’s event brings together leading scientists, physicians, and senior leaders to explore the brain and its engagement with the GI-nervous system axis in health and disease. Chief Executive Dr […]
UK biotech to manufacture novel medicines for Inflammatory Bowel Disease using spores of gut bacteria Three leading British biotechnology businesses have obtained grant funding from Innovate UK to investigate the manufacture of a new class of medicines, targeting a range of clinical conditions through interaction with the human microbiome. The novel and highly innovative approach […]
CHAIN has been awarded £0.5M grant funding from Innovate UK, the UK’s Innovation agency, to expand its range of biotechnology products. Building on a successful synthetic biology program, the grants support further development of CHAIN’s proprietary Clostridium platform for therapeutic and specialty chemical applications. A two-year project will focus on the development of novel therapeutics […]
CHAIN Biotechnology Ltd develops Clostridium-based microbial technology for high-value healthcare products. We produce novel 2nd generation live biotherapeutic products for chronic gut-related diseases.
CHAIN is developing several therapeutic compounds targeted to the gut microbiome in the large intestine that can be delivered by our CADD™ technology. Our lead product targets Inflammatory Bowel Disease.